After hashing out comeback plans, Deciphera looks to raise $125M from stock sale
Earlier in January, Deciphera outlined plans for a new Phase III study of its tyrosine kinase inhibitor Qinlock, still hoping to move it into an …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
